Assistant Professor of Hematology 🇵🇪 #IMG #ClassicalHeme🥰 #GlobOnc #MedEd #HemOnc #StoptheClot #WomenInMedicine #Trujillana #LatinaWomeninHeme #hemefan🩸
Chicago, IL
Joined May 2019
- Tweets3.3K
- Following2.4K
- Followers3.3K
- Likes7.5K
Many times I was told I was dreaming too much....or that I was not good enough...and here I am. Grateful that I have few people that have believed in me throughout these years...Representation matters. Soy latina, peruana y orgullosamente hematologa en EEUU! More to come!
🌎🌍
Pamela Contreras Chavez retweeted
Ana & Rana is a heartwarming bilingual children’s story about a young Latina girl with a big dream: to become a doctor and care for her community. 🐸🩺
🛍️ Purchase your copy online or in person at the LMSA National Conference! 📚✨
national.lmsa.net/store/unca…
Amazing work!!!!! @AndreaAnampaG !!!
My proposal to @ASCO is now a Board-approved Position Statement on removing barriers for pediatric and AYA patients to participate in clinical trials. AYAs enroll at <20%
asco.org/news-initiatives/po… #AYACancer #ClinicalTrials #PediatricOncology #HealthPolicy
ALT ASCO's position statement addresses persistent barriers to clinical trial participation for pediatric and AYA (ages 15–39) cancer patients. While 50–60% of children with cancer enroll in trials, AYA enrollment sits below 20%, and their outcomes haven't improved at the same pace. The statement identifies three core problems: inadequate funding (only ~4% of federal cancer research dollars go to pediatric cancer, with almost no industry investment), restrictive age-based eligibility criteria, and limited geographic access since most trials are concentrated at academic centers. ASCO recommends: (1) dedicated federal funding for pediatric and AYA research, (2) including adolescents 12+ in adult trials when biologically appropriate — shifting from age-based to biology-based eligibility, and (3) expanding trials into community settings with travel and lodging support for families.
I am so so ready! I cant wait to attend my first ever #ISTH meeting as a Latina Hematologist in the US! #Thrombosis #Bleeding disorders I am just thrilled to learn as much how much advancements in the thriving field of #classical heme has happened!!!!! PARIS here I go!!
The road to Paris starts with your science. Are you ready to answer the call? Abstract submission is officially open for #ISTH2026.
Don’t wait—submit today: isthcongress.org/abstracts #ISTHRoadToParis
Pamela Contreras Chavez retweeted
I used to enjoy teaching on Twitter (when it was a reasonable place to engage) before I lost my previous account.
I'm wondering if people would still be interested in learning some hematology here!
🙋🏽 if you are interested 🙌🏽
Pamela Contreras Chavez retweeted
Launching HemeOncBuddy.org today = 5 years of hard work!
A free, oncologist-curated heme/onc resource — built for the bedside, the boards, and everyone in between.
Every entry cross-checked against OpenEvidence
@openevidence = Zero errors flagged.
What's inside ↓
Pamela Contreras Chavez retweeted
Happy to share our chapter in the 2nd edition of Classical Hematology:
“Hemostasis Disturbances in Acute Leukemias and Myelodysplastic Neoplasms”
Honored to collaborate with Syed Ali Abutalib and Jean M. Connors on this practical Q&A-based review covering:
🔹 Bleeding & thrombosis in acute leukemias/MDS
🔹 Pegasparaginase-associated coagulopathy
🔹 DIC, hypofibrinogenemia & CNS thrombosis
🔹 Real-world diagnostic and management challenges
Grateful to contribute to this outstanding educational resource in hematology.
#Leusm #mdssm #Thrombosis #Hemostasis #MedEd #AML #ALL
Just a Classical/Nonmalignant #latina🥰 hematologist representing the #bilingual talent of managing complex blood disorders and serving my #hispanic Community!!!! 🫶
@LatinasInMed24 @IMG_Advocate @ImgJourney @WomeninOnc
Congratulations @HenryZelada2 !
Latinos in Medicine!! Representation matters !!!
Super proud of you my friend. @IMG_Advocate @ImgJourney @StoriesImg
This quoted post is unavailable.
Pamela Contreras Chavez retweeted
Hereditary haemolytic anaemias represent the most prevalent group of genetic disorders worldwide.
A Therapeutics paper provides a comprehensive overview of pyruvate kinase activators as a novel therapeutic approach for hereditary haemolytic anaemias: spkl.io/6019AFnYF
ALT Figure illustrating the effect of pyruvate kinase activators on cellular mechanisms that influence cell survival. Figure created using biorender.com. Copyright: 2026 Elsevier Ltd. All rights are reserved.
Pamela Contreras Chavez retweeted
Congratulations to @RabiHannaMD my friend and colleague at @ClevelandClinic for leading the practice changing study on CRISPR gene editing for Sickle Cell Disease chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/nejm.org/doi/pdf/10.1056/NEJ… @NEJM @OncoAlert @IMG_Oncologists
Pamela Contreras Chavez retweeted
Thanks for supporting and highlighting my lab's research @isth
🎙️ New ISTH Pulse Podcast Episode: What does it take to turn fundamental science into real advances in patient care? Our host sits down with Marie Hollenhorst to discuss her path into thrombosis and hemostasis research.
Listen: soundcloud.com/isth_thepulse…
An honor to contribute with something to this amazing oncology team from Spain lead by Dr Barbacid 🤩✌🏻in order to continue with very hopeful studies for pancreatic cancer cure research. Spread the hope. Donate. Link below in post!!! ⬇️ Increible!!!! @OncoAlert @ASCO
🔴El Dr. Mariano Barbacid y su equipo, financiados por #CRISContraelCáncer, han logrado curar el cáncer de páncreas en ratones, de forma duradera y sin efectos secundarios.
Pero necesitamos tu ayuda para que esto sea una realidad en pacientes.
DONA AQUÍ👉ow.ly/b5cA50Y6Ou7
Board certified hematologist ❤️
Would like to thank all my
mentors, 2 of them in these pictures who have been key in the path of becoming a hematologist!
Thank you Dr Connors and Dr Langer for showing me the way 🌟
LATINOS in HEMATOLOGY!!!
PERU 🇵🇪 presente!!
Pamela Contreras Chavez retweeted
In @NEJM, we discuss the growing fiscal challenges posed by GLP-1s and present a new opportunity for payers to consider: liraglutide. We review the comparative efficacy and argue that this newly generic GLP-1 may better balance access and affordability.
nejm.org/doi/full/10.1056/NE…
Pamela Contreras Chavez retweeted
Pre-emptive rituximab stopped relapses in our iTTP patients. 💪
After 3-5 prior relapses each, and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 - 68 months)
This is a big deal for a tough disease. Grateful to my mentor Dr. Khawandanah & our team. More studies needed, but hope is here.
Super thankful to all of ours mentor - Dr James N George, truly a difference maker in these patients, and in his mentees careers.
The fellows at @StephensonCC continue to shine, we have the best leadership and the fellowship program director (#DrSamiIbrahimi) 🤩
#TTP #iTTP #MedTwitter #HopeInResearch
One of the most challenging consults in the hematology inpatient workflow. -Amazing thread! 🙌🌟
My 12-Step Thrombocytopenia Workup 🧵
(Not Medical Advice)
1. Review baseline counts first. Rule out pseudothrombocytopenia.
2. Evaluate for critical conditions: TTP, HIT, or DIC?
• Assess heparin exposure - Calculate 4T score.
• Peripheral smear for schistocytes.
• Check LDH/Haptoglobin/Bilirubin, PT/aPTT/Fibrinogen.
3. Assess for acute leukemia or bone marrow involvement?
• Examine peripheral smear for abnormal/neoplastic cells.
• Consider imaging if clinically indicated.
• Do we need a bone marrow exam?
4. Active life-threatening bleeding? Do we need a platelet transfusion?
5. Review drug-induced thrombocytopenia. Always consult latest literature for implicated medications.
6. Investigate secondary causes:
• Nutritional deficiencies: B12, Folate, Copper, Zinc.
• Infections: HIV, Hepatitis, CMV, EBV, HSV (clinically guided).
• Sepsis leading to DIC.
• Endocrine disorders: TSH, Free T4.
7. Review imaging for cirrhosis/splenomegaly. If inconclusive, obtain abdominal ultrasound.
8. Consider mechanical causes: Dialysis/ECMO/IABP/cardiopulmonary bypass/artificial heart valve?
9. Evaluate pregnancy-related disorders: HELLP, AFLP, gestational thrombocytopenia.
10. Assess for autoimmune conditions if clinically warranted. Consider SLE and other rheumatological diseases.
11. Consider rare but serious differentials:
• CAPS, other TMA causes, PNH
• Post-transfusion purpura, HLH
• Pursue only with appropriate clinical suspicion
12. If no clear etiology identified, consider ITP as diagnosis of exclusion.
📋 Key Clinical Considerations:
• Critically ill patients frequently have multifactorial thrombocytopenia [A combination of some of the above].
• Primary HLH presenting de novo in adults is exceedingly rare.
• Thrombocytopenia with thrombosis: Consider DIC, TTP, HIT, PNH, or VITT.
[Image AI Generated]
#Hematology #MedTwitter
